{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T20:09:16Z","timestamp":1774814956405,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-79600-y","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T17:44:02Z","timestamp":1736012642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world experience with nucleos(t)ide analogue therapy and patient survival rates in chronic viral hepatitis B treatment centers in Eritrea"],"prefix":"10.1038","volume":"15","author":[{"given":"Michael Berhe","family":"Solomon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0275-2279","authenticated-orcid":false,"given":"Ghirmay Ghebrekidan","family":"Ghebremeskel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8013-0785","authenticated-orcid":false,"given":"Oliver Okoth","family":"Achila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aron Rezene","family":"Mebrahtu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5337-399X","authenticated-orcid":false,"given":"Mohammed Elfatih","family":"Hamida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Araia Berhane","family":"Mesfin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"79600_CR1","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","volume":"7","author":"Global National Burden of Hepatitis B","year":"2022","unstructured":"Global National Burden of H\u2013epatitis B. 1990\u20132019: A systematic analysis for the global burden of disease study 2019. Lancet Gastroenterol. Hepatol. 7, 796\u2013829 (2022). (eng).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"79600_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","volume":"8","author":"F Cui","year":"2023","unstructured":"Cui, F. et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol. Hepatol. 8, 332\u2013342 (2023). (eng).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"79600_CR3","unstructured":"Hepatitis, B. Accessed date: 2024 20 October. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b"},{"key":"79600_CR4","doi-asserted-by":"publisher","first-page":"986020","DOI":"10.3389\/fpubh.2023.986020","volume":"11","author":"GN Makokha","year":"2023","unstructured":"Makokha, G. N., Zhang, P., Hayes, C. N., Songok, E. & Chayama, K. The burden of Hepatitis B virus infection in Kenya: A systematic review and meta-analysis. Front. Public. Health. 11, 986020 (2023). (eng).","journal-title":"Front. Public. Health"},{"key":"79600_CR5","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s11901-019-00478-w","volume":"18","author":"S Nayagam","year":"2019","unstructured":"Nayagam, S. & Thursz, M. Strategies for global elimination of chronic HBV infection: 2019 update. Curr. Hepatol. Rep. 18, 300\u2013309 (2019).","journal-title":"Curr. Hepatol. Rep."},{"key":"79600_CR6","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.3748\/wjg.v27.i28.4603","volume":"27","author":"P Torre","year":"2021","unstructured":"Torre, P., Aglitti, A., Masarone, M. & Persico, M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J. Gastroenterol. 27, 4603 (2021).","journal-title":"World J. Gastroenterol."},{"key":"79600_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0140-6736(22)01377-0","volume":"400","author":"L The","year":"2022","unstructured":"The, L. Viral hepatitis elimination: A challenge, but within reach. Lancet. 400, 251 (2022). (eng).","journal-title":"Lancet"},{"key":"79600_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","volume":"4","author":"GS Cooke","year":"2019","unstructured":"Cooke, G. S. et al. Accelerating the elimination of viral hepatitis: A Lancet Gastroenterology & hepatology commission. Lancet Gastroenterol. Hepatol. 4, 135\u2013184 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"79600_CR9","doi-asserted-by":"publisher","first-page":"882878","DOI":"10.3389\/fmed.2022.882878","volume":"9","author":"J Wu","year":"2022","unstructured":"Wu, J., Wang, Y., Zhu, C. & Lin, W. Editorial: Diagnosis, treatment, and prognosis of viral Hepatitis. Front. Med. (Lausanne). 9, 882878 (2022). (eng).","journal-title":"Front. Med. (Lausanne)"},{"key":"79600_CR10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin, P. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. Lancet. 381, 468\u2013475 (2013).","journal-title":"Lancet"},{"key":"79600_CR11","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/S2468-1253(17)30295-9","volume":"2","author":"CW Spearman","year":"2017","unstructured":"Spearman, C. W. et al. Hepatitis B in sub-saharan Africa: Strategies to achieve the 2030 elimination targets. Lancet Gastroenterol. Hepatol. 2, 900\u2013909 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"79600_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12992-023-00922-z","volume":"19","author":"M Wang","year":"2023","unstructured":"Wang, M., Yan, L., Wang, J., Jin, Y. & Zheng, Z-J. Global burden of hepatitis B attributable to modifiable risk factors from 1990 to 2019: A growing contribution and its association with socioeconomic status. Globalization Health. 19, 23 (2023).","journal-title":"Globalization Health"},{"key":"79600_CR13","unstructured":"Division, C. D. C. in Guidelines for the care and Treatment of Persons Diagnosed with Chronic Hepatitis B and C Virus Infection in. (eds Division, C. D. C.) (Ministry of Health, 2018)."},{"key":"79600_CR14","doi-asserted-by":"publisher","first-page":"11323","DOI":"10.1038\/s41598-021-90836-w","volume":"11","author":"ME Hamida","year":"2021","unstructured":"Hamida, M. E. et al. Prevalence of hepatitis B virus genotypes among patients with liver disease in Eritrea. Sci. Rep. 11, 11323 (2021). (eng).","journal-title":"Sci. Rep."},{"key":"79600_CR15","unstructured":"Organization, W. H. Combating Hepatitis B and C to Reach Elimination by 2030: Advocacy Brief (World Health Organization, 2016)."},{"key":"79600_CR16","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 67, 1560\u20131599 (2018).","journal-title":"Hepatology"},{"key":"79600_CR17","unstructured":"WHO welcomes Egypt. \u2019s support to 14 African countries in their fight against hepatitis C. Accessed date: 2024 20 October. https:\/\/www.afro.who.int\/news\/who-welcomes-egypts-support-14-african-countries-their-fight-against-hepatitis-c"},{"key":"79600_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"S Sarin","year":"2016","unstructured":"Sarin, S. et al. Asian-pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hep. Intl. 10, 1\u201398 (2016).","journal-title":"Hep. Intl."},{"key":"79600_CR19","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.3748\/wjg.v27.i36.6025","volume":"27","author":"E Amponsah-Dacosta","year":"2021","unstructured":"Amponsah-Dacosta, E. Hepatitis B virus infection and hepatocellular carcinoma in sub-saharan Africa: Implications for elimination of viral hepatitis by 2030? World J. Gastroenterol. 27, 6025 (2021).","journal-title":"World J. Gastroenterol."},{"key":"79600_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/jmv.20544","volume":"78","author":"M Vray","year":"2006","unstructured":"Vray, M. et al. Molecular epidemiology of hepatitis B virus in Dakar, Senegal. J. Med. Virol. 78, 329\u2013334 (2006).","journal-title":"J. Med. Virol."},{"key":"79600_CR21","doi-asserted-by":"crossref","unstructured":"Ghabeshi, S., Sharifi, Z., Hosseini, S. M. & Shooshtari, M. M. Correlation between viral load of HBV in chronic hepatitis B patients and precore and basal core promoter mutations. Hepat. Monthly ;13. (2013).","DOI":"10.5812\/hepatmon.7415"},{"key":"79600_CR22","first-page":"453","volume":"5","author":"H Azhari","year":"2022","unstructured":"Azhari, H. et al. Real-world tertiary referral centre experience stopping nucleos (t) ide analogue therapy in patients with chronic hepatitis B. Can. Liver J. 5, 453\u2013465 (2022).","journal-title":"Can. Liver J."},{"key":"79600_CR23","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1111\/jgh.15664","volume":"36","author":"JCT Lai","year":"2021","unstructured":"Lai, J. C. T. et al. Secular trend of treatment uptake in patients with chronic hepatitis B: a territory-wide study of 135 395 patients from 2000 to 2017. J. Gastroenterol. Hepatol. 36, 3487\u20133499 (2021).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"79600_CR24","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.3748\/wjg.v28.i29.3793","volume":"28","author":"B Gnyawali","year":"2022","unstructured":"Gnyawali, B., Pusateri, A., Nickerson, A., Jalil, S. & Mumtaz, K. Epidemiologic and socioeconomic factors impacting hepatitis B virus and related hepatocellular carcinoma. World J. Gastroenterol. 28, 3793 (2022).","journal-title":"World J. Gastroenterol."},{"key":"79600_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12878-019-0136-5","volume":"19","author":"YT Keleta","year":"2019","unstructured":"Keleta, Y. T. et al. Seroprevalence of transfusion transmitted infections among blood donors in Gash Barka Zonal Blood Transfusion Center, Barentu, Eritrea, 2014 through 2017. BMC Hematol. 19, 1\u20139 (2019).","journal-title":"BMC Hematol."},{"key":"79600_CR26","doi-asserted-by":"publisher","first-page":"11941","DOI":"10.3748\/wjg.v21.i42.11941","volume":"21","author":"R Zampino","year":"2015","unstructured":"Zampino, R. et al. Hepatitis B virus burden in developing countries. World J. Gastroenterol. 21, 11941 (2015).","journal-title":"World J. Gastroenterol."},{"key":"79600_CR27","doi-asserted-by":"publisher","first-page":"100152","DOI":"10.1016\/j.jhepr.2020.100152","volume":"2","author":"VWK Hui","year":"2020","unstructured":"Hui, V. W. K. et al. Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. JHEP Rep. 2, 100152 (2020).","journal-title":"JHEP Rep."},{"key":"79600_CR28","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jhep.2019.01.037","volume":"70","author":"H Aberra","year":"2019","unstructured":"Aberra, H. et al. The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia. J. Hepatol. 70, 1065\u20131071 (2019).","journal-title":"J. Hepatol."},{"key":"79600_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41467-022-35729-w","volume":"14","author":"A Johannessen","year":"2023","unstructured":"Johannessen, A. et al. Systematic review and individual-patient-data meta-analysis of non-invasive fibrosis markers for chronic hepatitis B in Africa. Nat. Commun. 14, 45 (2023). (eng).","journal-title":"Nat. Commun."},{"key":"79600_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin, S. K. et al. Asian-pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol. Int. 10, 1\u201398 (2016). (eng).","journal-title":"Hepatol. Int."},{"key":"79600_CR31","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"P Lampertico","year":"2017","unstructured":"Lampertico, P. et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370\u2013398 (2017).","journal-title":"J. Hepatol."},{"key":"79600_CR32","doi-asserted-by":"publisher","first-page":"e1060","DOI":"10.1016\/S2214-109X(18)30344-9","volume":"6","author":"S Vento","year":"2018","unstructured":"Vento, S., Dzudzor, B., Cainelli, F. & Tachi, K. Liver cirrhosis in sub-saharan Africa: Neglected, yet important. Lancet Glob Health. 6, e1060\u2013e1061 (2018). (eng).","journal-title":"Lancet Glob Health"},{"key":"79600_CR33","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12876-021-01789-3","volume":"21","author":"ME Hamida","year":"2021","unstructured":"Hamida, M. E., Raja, S. M., Seyoum, Y., Elkhidir, I. M. & Tekle, F. Prevalence of chronic hepatitis B phases in Eritrean patients: A laboratory-based cross-sectional study. BMC Gastroenterol. 21, 198 (2021).","journal-title":"BMC Gastroenterol."},{"key":"79600_CR34","doi-asserted-by":"publisher","first-page":"e000060","DOI":"10.1136\/bmjgast-2015-000060","volume":"2","author":"VD Vu","year":"2015","unstructured":"Vu, V. D. et al. Long-term follow-up and suboptimal treatment rates of treatment-eligible chronic hepatitis B patients in diverse practice settings: A gap in linkage to care. BMJ Open. Gastroenterol. 2, e000060 (2015). (eng).","journal-title":"BMJ Open. Gastroenterol."},{"key":"79600_CR35","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/liv.14744","volume":"41","author":"B Surial","year":"2021","unstructured":"Surial, B. et al. Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-saharan Africa: Systematic review and meta-analysis. Liver Int. 41, 710\u2013719 (2021). (eng).","journal-title":"Liver Int."},{"key":"79600_CR36","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/jvh.13247","volume":"27","author":"MW Sonderup","year":"2020","unstructured":"Sonderup, M. W. et al. Hepatitis B in sub-saharan Africa-How many patients need therapy? J. Viral Hepat. 27, 560\u2013567 (2020). (eng).","journal-title":"J. Viral Hepat."},{"key":"79600_CR37","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/17474124.2018.1474097","volume":"12","author":"C B\u00e9guelin","year":"2018","unstructured":"B\u00e9guelin, C., Fall, F., Seydi, M. & Wandeler, G. The current situation and challenges of screening for and treating hepatitis B in sub-saharan Africa. Expert Rev. Gastroenterol. Hepatol. 12, 537\u2013546 (2018). (eng).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"79600_CR38","doi-asserted-by":"publisher","first-page":"100623","DOI":"10.1016\/j.jhepr.2022.100623","volume":"5","author":"T Mitchell","year":"2023","unstructured":"Mitchell, T., Nayagam, J. S., Dusheiko, G. & Agarwal, K. Health inequalities in the management of chronic hepatitis B virus infection in patients from Sub-saharan Africa in high-income countries. JHEP Rep. 5, 100623 (2023). (eng).","journal-title":"JHEP Rep."},{"key":"79600_CR39","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/gutjnl-2015-309260","volume":"65","author":"M Lemoine","year":"2016","unstructured":"Lemoine, M. et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut. 65, 1369\u20131376 (2016). (eng).","journal-title":"Gut"},{"key":"79600_CR40","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12876-020-01581-9","volume":"20","author":"YA Nartey","year":"2020","unstructured":"Nartey, Y. A. et al. Ambulatory end-stage liver disease in Ghana; patient profile and utility of alpha fetoprotein and aspartate aminotransferase: Platelet ratio index. BMC Gastroenterol. 20, 428 (2020). (eng).","journal-title":"BMC Gastroenterol."},{"key":"79600_CR41","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/hep.27382","volume":"61","author":"G Xiao","year":"2015","unstructured":"Xiao, G., Yang, J. & Yan, L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A systemic review and meta-analysis. Hepatology. 61, 292\u2013302 (2015). (eng).","journal-title":"Hepatology"},{"key":"79600_CR42","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jhep.2019.03.009","volume":"70","author":"G Dusheiko","year":"2019","unstructured":"Dusheiko, G. & Lemoine, M. An appraisal of the WHO Hepatitis B treatment guidelines applicability to africans. J. Hepatol. 70, 1046\u20131048 (2019). (eng).","journal-title":"J. Hepatol."},{"key":"79600_CR43","doi-asserted-by":"crossref","unstructured":"Nguyen, M. H., Wong, G., Gane, E., Kao, J. H. & Dusheiko, G. Hepatitis B Virus: Advances in Prevention, diagnosis, and Therapy. Clin. Microbiol. Rev. 2020;33. (eng).","DOI":"10.1128\/CMR.00046-19"},{"key":"79600_CR44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cld.2019.04.008","volume":"23","author":"A Vittal","year":"2019","unstructured":"Vittal, A. & Ghany, M. G. WHO guidelines for prevention, care and treatment of individuals infected with HBV: A US perspective. Clin. Liver Dis. 23, 417\u2013432 (2019).","journal-title":"Clin. Liver Dis."},{"key":"79600_CR45","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/bmj.38050.593634.63","volume":"328","author":"HC Kim","year":"2004","unstructured":"Kim, H. C. et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: Prospective cohort study. Bmj. 328, 983 (2004). (eng).","journal-title":"Bmj"},{"key":"79600_CR46","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","volume":"134","author":"M Kumar","year":"2008","unstructured":"Kumar, M. et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology. 134, 1376\u20131384 (2008). (eng).","journal-title":"Gastroenterology"},{"key":"79600_CR47","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jhep.2007.07.022","volume":"47","author":"M Lai","year":"2007","unstructured":"Lai, M., Hyatt, B. J., Nasser, I., Curry, M. & Afdhal, N. H. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J. Hepatol. 47, 760\u2013767 (2007). (eng).","journal-title":"J. Hepatol."},{"key":"79600_CR48","doi-asserted-by":"publisher","first-page":"e0123140","DOI":"10.1371\/journal.pone.0123140","volume":"10","author":"C Odhiambo","year":"2015","unstructured":"Odhiambo, C. et al. Evaluation of locally established reference intervals for hematology and biochemistry parameters in Western Kenya. PLoS One. 10, e0123140 (2015). (eng).","journal-title":"PLoS One"},{"key":"79600_CR49","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1186\/s13104-017-3087-6","volume":"10","author":"OO Achila","year":"2017","unstructured":"Achila, O. O. et al. Biochemistry reference intervals for healthy elderly population in Asmara, Eritrea. BMC Res. Notes. 10, 748 (2017). (eng).","journal-title":"BMC Res. Notes"},{"key":"79600_CR50","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11606-010-1549-9","volume":"26","author":"T Juday","year":"2011","unstructured":"Juday, T. et al. Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment. J. Gen. Intern. Med. 26, 239\u2013244 (2011). (eng).","journal-title":"J. Gen. Intern. Med."},{"key":"79600_CR51","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1128\/AAC.04454-14","volume":"59","author":"YB Lee","year":"2015","unstructured":"Lee, Y. B. et al. Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B. Antimicrob. Agents Chemother. 59, 972\u2013978 (2015). (eng).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"79600_CR52","doi-asserted-by":"publisher","first-page":"828","DOI":"10.5009\/gnl16484","volume":"11","author":"J Park","year":"2017","unstructured":"Park, J. et al. Effects of entecavir and tenofovir on renal function in patients with hepatitis B virus-related compensated and decompensated cirrhosis. Gut Liver. 11 (6), 828\u2013834. https:\/\/doi.org\/10.5009\/gnl16484 (2017). PMID: 28651305; PMCID: PMC5669599.","journal-title":"Gut Liver"},{"key":"79600_CR53","doi-asserted-by":"publisher","first-page":"7214020","DOI":"10.1155\/2016\/7214020","volume":"2016","author":"L Chen","year":"2016","unstructured":"Chen, L. et al. Efficacy of tenofovir-based combination therapy versus tenofovir monotherapy in chronic hepatitis B patients presenting with suboptimal responses to pretreatment: A meta-analysis. Gastroenterol. Res. Pract. 2016, 7214020 (2016). (eng).","journal-title":"Gastroenterol. Res. Pract."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79600-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79600-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79600-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T07:03:39Z","timestamp":1736060619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79600-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["79600"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79600-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4301242\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"21 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data were collected from the Chronic Viral Hepatitis Care Center in ONRH and HNRH focal personnel with incentives and material support obtained from the Eritrean Ministry of Health, CDC division.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial support"}}],"article-number":"824"}}